What are the IDSA (Infectious Diseases Society of America) guidelines for the specific infection or clinical scenario?

IDSA Guidelines Overview

The Infectious Diseases Society of America (IDSA) publishes comprehensive, evidence-based clinical practice guidelines across multiple infectious disease domains, with recent major updates in 2024-2025 covering complicated intra-abdominal infections, antimicrobial-resistant gram-negative infections, COVID-19 management, and pediatric acute bacterial arthritis.

Current IDSA Guideline Portfolio (2024-2025)

Complicated Intra-Abdominal Infections (2024)

• Scope includes: acute appendicitis, acute cholecystitis (acalculous and calculous), acute cholangitis, acute diverticulitis, abdominal abscess, secondary bowel perforation, and acute necrotizing pancreatitis 1
• Population coverage: adults (community-acquired and hospital-acquired), children, and pregnant individuals 1
• Structure: The 2024 update replaces the 2010 guideline and is published as eight separate manuscripts covering risk assessment, diagnostic imaging, and microbiological evaluation, with subsequent parts addressing antimicrobial therapy and source control 1
• Methodology: Uses GRADE approach for evidence appraisal, with strong recommendations made when the course of action applies to most patients with few exceptions, and conditional recommendations when many exceptions exist requiring shared decision-making 1
• Evidence quality: High-quality evidence was lacking for all recommendations; the panel provided limited clinical guidance for reasonable approaches rather than no guidance where knowledge gaps existed 1

Antimicrobial-Resistant Gram-Negative Infections (2024)

• Organisms covered: Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR P. aeruginosa), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia 2
• Geographic focus: United States-specific due to differences in AMR epidemiology and anti-infective availability internationally 2
• Content: Provides preferred and alternative treatment approaches assuming organism identification and susceptibility results are known, with brief discussions of empiric treatment, oral transition, duration, and other management considerations 2
• Applicability: Recommendations apply to both adult and pediatric populations, though dosing provided only for adults 2
• Key recommendation: Consultation with an infectious diseases specialist is recommended for all AMR infections 2
• Currency: Current as of December 31,2023, with periodic updates available at www.idsociety.org/practice-guideline/amr-guidance/ 2

COVID-19 Treatment and Management (2025)

• Latest update includes: Four new recommendations covering pemivibart for pre-exposure prophylaxis in immunocompromised persons, vilobelimab for critical illness, and abatacept or infliximab for severe or critical illness 3
• Population: Adults, children, and pregnant individuals 3
• Methodology: GRADE approach with systematic literature reviews 3
• Structure: Focused updates released periodically rather than comprehensive revisions 3

COVID-19 Molecular Diagnostic Testing (2021)

• Focus: SARS-CoV-2 nucleic acid amplification tests for direct detection in respiratory specimens 4
• Recommendations: 17 diagnostic recommendations addressing symptomatic individuals, asymptomatic contacts, and asymptomatic individuals without known exposure when results impact isolation/quarantine/PPE decisions, surgical eligibility, or transplantation timing 4
• Evidence quality: Moderate to very low quality in current literature 4
• Key principle: Universal access to accurate SARS-CoV-2 nucleic acid testing is critical for patient care, hospital infection prevention, and public health response 4

COVID-19 Infection Prevention for Healthcare Personnel (2020)

• Focus: Personal protective equipment (PPE) recommendations for HCP caring for patients with suspected or known COVID-19 5
• Standards of care addressed: Conventional, contingency, and crisis standards 5
• Recommendations: Eight specific recommendations on PPE use, with particular attention to aerosol-generating procedures that may have higher transmission risk 5
• Evidence base: Combination of direct and indirect evidence 5

Pediatric Acute Bacterial Arthritis (2024)

• Joint development: IDSA and Pediatric Infectious Diseases Society (PIDS) 6
• Target audience: Healthcare professionals caring for children with acute bacterial arthritis, including pediatric infectious diseases specialists and orthopedic surgeons 6
• Content: Recommendations for diagnosis and treatment based on topic-specific systematic literature reviews 6
• Methodology: GRADE approach for rating certainty of evidence and strength of recommendations 6

IDSA Guideline Development Methodology

Panel Composition

• Multidisciplinary approach: Includes infectious diseases clinicians, pediatric infectious diseases specialists, surgeons, emergency medicine physicians, microbiologists, pharmacologists, and patient representatives 1, 6
• Conflict of interest management: Efforts made to minimize bias from conflicts of interest 6

Evidence Review Process

• Systematic literature reviews: Conducted by dedicated evidence review teams 1, 6
• GRADE methodology: Used to assess certainty of evidence and formulate recommendations across all recent guidelines 1, 3, 2, 6, 4, 5
• External endorsement: Relevant recommendations reviewed and endorsed by partner societies including European Society of Clinical Microbiology and Infectious Diseases (ESCMID), American Society for Microbiology (ASM), and PIDS 1

Recommendation Strength Classification

• Strong recommendations: Course of action applies to most patients with few exceptions 1
• Conditional recommendations: Suggested course applies to majority with many exceptions; shared decision-making important 1
• Knowledge gap statements: Provided when high-quality evidence lacking but clinical guidance still needed 1

Accessing IDSA Guidelines

All current IDSA guidelines are available at www.idsociety.org with periodic updates reflecting the rapidly evolving nature of infectious disease management, particularly for antimicrobial resistance and emerging pathogens like SARS-CoV-2 2, 4.